Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform

by Zacks Equity Research

QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.

Zacks Equity Research

Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?

by Zacks Equity Research

Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu

by Zacks Equity Research

QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.

Zacks Equity Research

QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit

by Zacks Equity Research

QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.

Zacks Equity Research

QIAGEN (QGEN) Develops Test for Research and CDx Application

by Zacks Equity Research

QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.

Zacks Equity Research

Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now

by Zacks Equity Research

QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.

Zacks Equity Research

QIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification

by Zacks Equity Research

QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.

Zacks Equity Research

QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus

by Zacks Equity Research

QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.